Breaking News, Collaborations & Alliances

Ariceum Therapeutics Partners with NorthStar for Ac-225 Supply

Will use NorthStar’s Ac-225 to radiolabel its proprietary peptide (SS0110) satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (SSTR2).

Author Image

By: Charlie Sternberg

Associate Editor

NorthStar Medical Radioisotopes, LLC, an innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of cancers, have signed a supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225).   Under the terms of the agreement, NorthStar will provide Ariceum with non-carrier...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters